Company Overview - Chongqing Dengkang Oral Care Products Co., Ltd. is located at 389 Haier Road, Jiangbei District, Chongqing, established on December 14, 2001, and listed on April 10, 2023 [1] - The company specializes in the research, production, and sales of oral care products [1] Revenue Composition - The main revenue sources are: Adult toothpaste 80.43%, Adult toothbrush 9.90%, Children's toothpaste 4.54%, Oral medical and beauty care products 2.44%, Children's toothbrush 1.76%, Electric toothbrush 0.81%, Other (supplement) 0.11% [1] Stock Performance - On September 4, Dengkang Oral Care's stock rose by 5.18%, trading at 42.65 yuan per share, with a transaction volume of 1.08 billion yuan and a turnover rate of 6.05%, resulting in a total market capitalization of 7.343 billion yuan [1] Fund Holdings - Dengkang Oral Care is a significant holding in the Zhonghai Consumption Mixed A Fund (398061), which increased its holdings by 15,400 shares in the second quarter, totaling 212,000 shares, representing 4.64% of the fund's net value [2] - The fund has achieved a floating profit of approximately 445,200 yuan as of the latest report [2] Fund Manager Performance - The fund manager, He Wenyin, has been in position for 3 years and 203 days, with the fund's total asset size at 303 million yuan [3] - During his tenure, the best fund return was 28.32%, while the worst was -32.34% [3]

Group 1 - The core viewpoint of the news is the performance and market position of Chongqing Dengkang Oral Care Products Co., Ltd, which saw a stock price increase of 5.18% to 42.65 CNY per share, with a total market capitalization of 7.343 billion CNY [1] - The company was established on December 14, 2001, and went public on April 10, 2023, focusing on the research, production, and sales of oral care products [1] - The revenue composition of the company includes adult toothpaste (80.43%), adult toothbrushes (9.90%), children's toothpaste (4.54%), oral medical and beauty care products (2.44%), children's toothbrushes (1.76%), electric toothbrushes (0.81%), and other products (0.11%) [1] Group 2 - From the perspective of fund holdings, Dengkang Oral Care is a significant investment for Nanhua Fund, with its Nanhua Ruiying Mixed Fund A holding 24,200 shares, accounting for 3.32% of the fund's net value, ranking as the sixth-largest holding [2] - The Nanhua Ruiying Mixed Fund A was established on August 16, 2017, with a current scale of 24.0118 million CNY, and has achieved a year-to-date return of 1.01% [2] - The fund's one-year return is 28.8%, ranking 4635 out of 7978 in its category, and since inception, it has returned 35.6% [2] Group 3 - The fund manager of Nanhua Ruiying Mixed Fund A is Xu Chao, who has been in the position for 9 years and 308 days, with a total asset scale of 650 million CNY [3] - Xu Chao's best fund return during his tenure is 129.63%, while the worst return is -18.74% [3] - The co-manager, Lu Yue, has been in the role for 1 year and 50 days, managing assets of 35.5714 million CNY, with a best return of 30.62% and a worst return of 29.78% during his tenure [3]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [7] Core Views - The company achieved a revenue of 840 million yuan in H1 2025, representing a year-on-year increase of 19.7%, and a net profit attributable to shareholders of 90 million yuan, up 17.6% year-on-year [1] - The online channel continues to drive growth, with e-commerce revenue reaching 300 million yuan in H1 2025, a significant increase of 86.9% year-on-year, while offline revenue remained stable at 540 million yuan, down 0.2% year-on-year [2] - The company is focusing on new product launches, particularly in the medical research category, which is expected to enhance growth and optimize product structure [4] - The company is the absolute leader in the sensitive toothpaste market, with strong growth potential through product upgrades and market expansion [5] Financial Performance Summary - In H1 2025, the gross margin was 52.6%, an increase of 5.7 percentage points year-on-year, while the net profit margin was 10.1%, a slight decrease of 0.18 percentage points year-on-year [3] - The company forecasts revenues of 1.863 billion yuan, 2.191 billion yuan, and 2.574 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 196 million yuan, 235 million yuan, and 282 million yuan [12]

Core Viewpoint - The company reported a strong performance in the first half of 2025, with revenue and net profit showing significant year-on-year growth, indicating a positive outlook for the business. Financial Performance - In H1 2025, the company achieved revenue of 842 million, a year-on-year increase of 19.7%, and a net profit attributable to shareholders of 85 million, up 17.6% [1] - Q2 2025 revenue reached 411 million, reflecting a 20.1% increase year-on-year, with net profit of 42 million, a 19.7% increase [1] - The company's net profit margin for H1 2025 was 10.12%, a slight decrease of 0.18 percentage points year-on-year [3] Revenue Breakdown - Adult toothpaste, which accounted for 80% of total revenue, saw a 23% increase in revenue [2] - Emerging oral care products generated revenue of 20 million, growing by 54.85% [2] - Electric toothbrush sales reached 6.816 million, a year-on-year increase of 37.33% [2] - E-commerce channel revenue surged to 325 million, a significant growth of 81.13%, increasing its share of total revenue from 25.53% to 38.62% [2] - Offline channel revenue was 517 million, showing a slight decline of 1.3% [2] Cost Structure and Profitability - The gross margin for H1 2025 was 52.61%, an increase of 5.68 percentage points year-on-year [3] - The sales expense ratio rose to 36.5%, up 6.3 percentage points, primarily due to increased investment in e-commerce and product upgrades [3] - Management, R&D, and financial expense ratios were 3.38%, 3.1%, and -0.7%, respectively, with management and R&D expenses decreasing year-on-year [3] Investment Outlook - The company maintains a stable offline channel while driving rapid growth in online channels through high-margin products [4] - The projected net profits for 2025-2027 are 204 million, 246 million, and 293 million, with year-on-year growth rates of 26.7%, 20.3%, and 19.4% respectively [4] - The current valuation corresponds to multiples of 37x, 31x, and 26x for the respective years [4]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][19]. Core Views - The company has shown stable growth in Q2, with revenue reaching 842 million, a year-on-year increase of 19.72%, and a net profit of 85 million, up 17.59% year-on-year. The growth is driven by the expansion of e-commerce channels and the successful development of high-margin products [1][7]. - The adult toothpaste category remains the core driver of revenue, achieving 677 million in sales, a 23% increase year-on-year, accounting for 80.43% of total revenue. Emerging categories like electric toothbrushes and oral medical care have also shown strong growth [2][7]. - The company has successfully leveraged e-commerce platforms, with revenue from e-commerce and other channels reaching 325 million, a significant increase of 81.13% year-on-year, enhancing its market position [2][8]. - The gross margin improved to 49.57%, driven by a higher proportion of high-margin products. The sales expense ratio increased due to the rising online sales proportion [3][9]. Financial Performance Summary - For the first half of 2025, the company reported revenue of 842 million and a net profit of 85 million, with Q2 alone contributing 411 million in revenue and 42 million in net profit [1][7]. - The company forecasts revenue growth to 2.01 billion in 2025, with a net profit of 224 million, reflecting a growth rate of 39.1% [4][17]. - The company maintains a stable operating capability, with inventory turnover days at 98 days and accounts receivable turnover days at 7 days [13]. Profitability and Valuation Metrics - The company is projected to have a PE ratio of 34 for 2025, decreasing to 22.2 by 2027, indicating an attractive valuation as earnings grow [4][17]. - The return on equity (ROE) is expected to rise from 10.1% in 2023 to 21.1% in 2027, reflecting improved profitability [4][17].